Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Colestipol May Quickly Eliminate Teriflunomide
Effect of Rituximab in Patients With Leucine-Rich, Glioma-Inactivated 1 Antibody-Associated Encephalopathy.
IFNγ-stimulated dendritic cell exosomes as a potential therapeutic for remyelination.
The role of T cell apoptosis in nervous system autoimmunity.
Immunology 2013
Treatment of Relapsing-Remitting Multiple Sclerosis After 24 Doses of Natalizumab: Evidence From an Italian Spontaneous, Prospective, and Observational Study (the TY-STOP Study).
Race to Erase MS Forum and Expo
Effects of Inhibitors of the Renin-Angiotensin System on the Efficacy of Interferon beta-1b: A post hoc Analysis of the BEYOND Study.
Tecfidera(®): an approach for repurposing.
Lights and shadows of cyclophosphamide in the treatment of multiple sclerosis.
Intensive immunosuppression in progressive multiple sclerosis. A randomized, three-arm study of high-dose intravenous cyclophosphamide, plasma exchange, and ACTH.
Treatment of acute transverse myelitis and its early complications.
CD8(+) T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease.
Pharmacokinetic properties and metabolism of idebenone.
Evidence for the efficacy of interferon beta-1b in delaying the onset of clinically definite multiple sclerosis in individuals with clinically isolated syndrome.
Stimulated PBMC-produced IFN-γ and TNF-α are associated with altered relapse risk in multiple sclerosis: results from a prospective cohort study.
Imaging outcomes for trials of remyelination in multiple sclerosis.
Reversal of Paralysis and Reduced Inflammation from Peripheral Administration of β-Amyloid in TH1 and TH17 Versions of Experimental Autoimmune Encephalomyelitis.
Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: A multi-center, retrospective analysis.
Morphological differentiation of oligodendrocytes requires activation of Fyn tyrosine kinase.
Environmental risk factors for multiple sclerosis. Part I: the role of infection.
Quality of life and depression in multiple sclerosis patients: longitudinal results of the BetaPlus study.
Treatment of neuromyelitis optica.
Testing effects of glatiramer acetate and fingolimod in an infectious model of CNS immune surveillance.
High dose cyclophosphamide preferentially targets naïve T (CD45/CD4/RA+) cells in CIDP and MS patients.

Pages